Mavefund EN
Pulse Biosciences Inc logo

Pulse Biosciences Inc

PLSE
Letzter Kurs (USD) US$47.57
Marktkapitalisierung (USD) US$3.4b
Kursänderung 12 Monate 206.11%
Loading the 12-month Mave Thesis and 1-month news signal

Branchen- und Sektorvergleich sowie weitere Research-Alternativen

Vergleich ansehen
West Pharmaceutical Services IncWST Vergleich Hologic IncHOLX Vergleich HaemoneticsHAE Vergleich Zoetis IncZTS Vergleich
Überblick Ergebnisbericht Kursverlauf Nachrichten Wettbewerber Gewinn je Aktie Eigenkapitalrendite Nettomarge Aktienrückkäufe Verschuldung Finanzberichte Finanzkennzahlen
Start Heute Aktien Watchlist

Pulse Biosciences Inc Überblick

Branche: Medical Instruments & Supplies

Sektor: Healthcare

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California. Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue t

Research-Überblick

Letztes Berichtsdatum 2026-08-06

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Pulse Biosciences Inc (PLSE): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
PLSE · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Medical Instruments & Supplies
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-06
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Pulse Biosciences Inc für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 06, 2026

Quarterly result summary

Revenue was $0.4M (reported). Net loss was -$0M.

Revenue $0.4M reported
Net loss -$0M reported

Was sich verändert hat

  • Revenue reported to $0.4M.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen
SEC filing FORM 10-Q Aug 06, 2026 SEC filing FORM 8-K Aug 06, 2026 SEC filing FORM 10-Q May 14, 2026 SEC filing FORM 8-K May 04, 2026 Earnings release PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MAY 4, 2026 - BUSINESS UPDATES AND FINANCIAL RESULTS May 04, 2026 SEC filing FORM 10-K/A Apr 30, 2026 SEC filing FORM 8-K Feb 19, 2026 Earnings release PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED FEBRUARY 19, 2026 - BUSINESS UPDATES AND FINANCIAL RESULTS Feb 19, 2026 SEC filing FORM 10-K Feb 19, 2026 SEC filing FORM 10-Q Nov 05, 2025 SEC filing FORM 8-K Nov 05, 2025

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 3.00/5
Pulse Biosciences Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

Eigenkapitalrendite

Score 0.16/5
Pulse Biosciences Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Pulse Biosci... PLSE US$3.4b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 0.27/5
Pulse Biosciences Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Pulse Biosci... PLSE US$3.4b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

Verschuldung

Score 2.92/5
Pulse Biosciences Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Pulse Biosci... PLSE US$3.4b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Pulse Biosciences Inc logo

Pulse Biosciences Inc

US$47.57

US$3.4b

-5.73%

206.11%